About
Advisor to Lightstone Ventures with over 25 years in product development and commercial leadership. Frank was CEO of Forma Therapeutics until its $1.1B acquisition by Novo Nordisk and served as Senior Vice President at Genentech leading global product strategy for late-stage portfolios.
Colleagues at Lightstone Ventures
Caroline Gaynor
Partner at Lightstone Ventures
Christina Isacson, Ph.D.
Partner at Lightstone Ventures
Doug Treco, Ph.D.
Advisor at Lightstone Ventures
H. Martin Seidel, Ph.D.
Advisor at Lightstone Ventures
Hank Plain
Founding Partner & Advisor at Lightstone Ventures
Hanson S. Gifford, III
Partner at Lightstone Ventures
Hong I. Wan, Ph.D.
Advisor at Lightstone Ventures
Jean George
Managing Partner at Lightstone Ventures